ReviewCurrent opinion in biotechnology2026
Discovery and development of penicillin-binding protein-type thioesterases as biocatalysts.
Review in Current opinion in biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cyclic peptides are promising drug candidates, but their synthesis, especially the synthesis of small, strained rings, remains challenging. Penicillin-binding protein-type thioesterases (PBP-TEs) have emerged as versatile biocatalysts that catalyze head-to-tail macrocyclization of nonribosomal peptides. Unlike canonical thioesterase domains, which catalyze diverse offloading outcomes, PBP-TEs exclusively promote head-to-tail cyclization, offering predictable reactivity. Their ability to act on diverse substrates in vitro further underscores their potential as tools for peptide drug discovery. This review highlights PBP-TE discovery and substrate scope investigation, along with recent advances in structural characterization and engineering, establishing these enzymes as a promising platform for the biocatalytic synthesis of cyclic peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.